Matches in SemOpenAlex for { <https://semopenalex.org/work/W2226196031> ?p ?o ?g. }
Showing items 1 to 76 of
76
with 100 items per page.
- W2226196031 endingPage "727" @default.
- W2226196031 startingPage "727" @default.
- W2226196031 abstract "727 Background: Patients treated with oxaliplatin are at risk for hypersensitivity reactions. The incidence of hypersensitivity reactions in clinical practice is estimated to be 12% to 20%. Prescribing information says that oxaliplatin is incompatible in solution with alkaline medications or media and must not be mixed these or administered simultaneously through the same infusion line. Because steroid is alkaline, the coinfusion of steroids and oxaliplatin can make oxaliplatin unstable due to the elevation of pH; further, the effectiveness of steroid in this therapy is unknown. Therefore, dexamethasone is routinely given to patients before they receive chemotherapy. However, we have reported that the pH after the addition of DEX (6.6 mg) to oxaliplatin was less than 7.4, and there is possibility that hypersensitivity reactions to oxaliplatin could have been prevented by coinfusion of dexamethasone (DEX) (Yoshida et al.2012 ASCO-GI) but just in a retrospective study. This prospective study was undertaken to evaluate the effectiveness of coinfusion of DEX to oxaliplatin for controlling hypersensitivity reactions caused by oxaliplatin. Methods: The AVOID trial is a prospective, multicenter, open-label, single-arm, phase II trial investigating hypersensitivity reactions to oxaliplatin could have been prevented by coinfusion of DEX. The study included 73 patients who received XELOX or XELOX +bevacizumab therapy for colorectal cancer. In all the patients, oxaliplatin (130mg/m²) was administered in combination with DEX (6.6 mg). Results: Hypersensitivity reactions developed in 3 patients (4.1%). Respiratory symptoms, ocular symptoms and anaphylaxis were not observed in 73 patients. The three patients experienced cutaneous reaction (erythema: grade1). Grade 3 or higher hemotoxicity was noted in 13.7% of the patients, and grade 3 or higher nonhematological toxicity was noted in 13.7%. The response rate was 58.1%. Conclusions: This trial supports coinfusion of dexamethasone and oxaliplatin reduced oxaliplatin-related hypersensitivity reactions. This effective approach should be considered for all patients who receive oxaliplatin, allowing treatment to be completed as planned. Clinical trial information: UMIN000009742." @default.
- W2226196031 created "2016-06-24" @default.
- W2226196031 creator A5001514470 @default.
- W2226196031 creator A5006958303 @default.
- W2226196031 creator A5046900502 @default.
- W2226196031 creator A5058315816 @default.
- W2226196031 creator A5062939532 @default.
- W2226196031 creator A5071060001 @default.
- W2226196031 creator A5072727806 @default.
- W2226196031 creator A5076651798 @default.
- W2226196031 creator A5084398419 @default.
- W2226196031 creator A5091529471 @default.
- W2226196031 creator A5021018726 @default.
- W2226196031 date "2015-01-20" @default.
- W2226196031 modified "2023-10-17" @default.
- W2226196031 title "A validation study of preventing oxaliplatin-induced hypersensitivity reactions by dexamethasone: The AVOID trial." @default.
- W2226196031 doi "https://doi.org/10.1200/jco.2015.33.3_suppl.727" @default.
- W2226196031 hasPublicationYear "2015" @default.
- W2226196031 type Work @default.
- W2226196031 sameAs 2226196031 @default.
- W2226196031 citedByCount "0" @default.
- W2226196031 crossrefType "journal-article" @default.
- W2226196031 hasAuthorship W2226196031A5001514470 @default.
- W2226196031 hasAuthorship W2226196031A5006958303 @default.
- W2226196031 hasAuthorship W2226196031A5021018726 @default.
- W2226196031 hasAuthorship W2226196031A5046900502 @default.
- W2226196031 hasAuthorship W2226196031A5058315816 @default.
- W2226196031 hasAuthorship W2226196031A5062939532 @default.
- W2226196031 hasAuthorship W2226196031A5071060001 @default.
- W2226196031 hasAuthorship W2226196031A5072727806 @default.
- W2226196031 hasAuthorship W2226196031A5076651798 @default.
- W2226196031 hasAuthorship W2226196031A5084398419 @default.
- W2226196031 hasAuthorship W2226196031A5091529471 @default.
- W2226196031 hasConcept C121608353 @default.
- W2226196031 hasConcept C126322002 @default.
- W2226196031 hasConcept C2776694085 @default.
- W2226196031 hasConcept C2777802072 @default.
- W2226196031 hasConcept C2780401358 @default.
- W2226196031 hasConcept C2780962732 @default.
- W2226196031 hasConcept C2993280485 @default.
- W2226196031 hasConcept C526805850 @default.
- W2226196031 hasConcept C71924100 @default.
- W2226196031 hasConcept C90924648 @default.
- W2226196031 hasConcept C98274493 @default.
- W2226196031 hasConceptScore W2226196031C121608353 @default.
- W2226196031 hasConceptScore W2226196031C126322002 @default.
- W2226196031 hasConceptScore W2226196031C2776694085 @default.
- W2226196031 hasConceptScore W2226196031C2777802072 @default.
- W2226196031 hasConceptScore W2226196031C2780401358 @default.
- W2226196031 hasConceptScore W2226196031C2780962732 @default.
- W2226196031 hasConceptScore W2226196031C2993280485 @default.
- W2226196031 hasConceptScore W2226196031C526805850 @default.
- W2226196031 hasConceptScore W2226196031C71924100 @default.
- W2226196031 hasConceptScore W2226196031C90924648 @default.
- W2226196031 hasConceptScore W2226196031C98274493 @default.
- W2226196031 hasIssue "3_suppl" @default.
- W2226196031 hasLocation W22261960311 @default.
- W2226196031 hasOpenAccess W2226196031 @default.
- W2226196031 hasPrimaryLocation W22261960311 @default.
- W2226196031 hasRelatedWork W1991468541 @default.
- W2226196031 hasRelatedWork W2000957761 @default.
- W2226196031 hasRelatedWork W2037428781 @default.
- W2226196031 hasRelatedWork W2066919805 @default.
- W2226196031 hasRelatedWork W2077615248 @default.
- W2226196031 hasRelatedWork W2098707609 @default.
- W2226196031 hasRelatedWork W2316610093 @default.
- W2226196031 hasRelatedWork W2409507836 @default.
- W2226196031 hasRelatedWork W2545945608 @default.
- W2226196031 hasRelatedWork W4361823821 @default.
- W2226196031 hasVolume "33" @default.
- W2226196031 isParatext "false" @default.
- W2226196031 isRetracted "false" @default.
- W2226196031 magId "2226196031" @default.
- W2226196031 workType "article" @default.